Background: The efficacy and safety of adding an angiotensin receptor blocker (ARB) in
heart failure (HF) patients already taking an angiotensin‐converting enzyme‐inhibitor (ACE …

Background Benefits and harms of the use of LCZ696 (sacubitril/valsartan, S/V), a
combination of a neprilysin inhibitor and an angiotensin receptor blocker (ARB), in heart …

puted placebo analysis). 21 In this analysis, losartan 50 mg once daily could not be shown
to be better than placebo. Concern that the dose of losartan was too low in this trial (and in …

December 2001 Volume 2 Number 4 p= 0.16). Moreover, since it was designed as a
superiority trial, the study did not have sufficient power to test for equivalence or non …

BACKGROUND: Blockade of the renin-angiotensin system with angiotensin-converting
enzyme inhibitors improves outcomes and symptoms in patients with heart failure (HF). We …

Background There are limited data on the efficacy, safety, and tolerability of
sacubitril/valsartan (S/V) in heart failure with a reduced ejection fraction (HFrEF) patients not …

The most recent trials of ARBs in heart failure and myocardial infarction patients suggest a
role for angiotensin receptor blockers in patients with heart failure who are intolerant to ACE …

Drugs that inhibit the renin–angiotensin system were introduced for the treatment of chronic
heart failure 35 years ago. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin …

In clinical heart failure (HF) the renin–angiotensin–aldosterone system is an important
component of neurohormonal activation. Angiotensin-converting enzyme inhibitors have …

Valsartan is a widely used, efficacious and very well-tolerated antihypertensive agent. By
specifically blocking the action of angiotensin II on the angiotensin Type 1 receptor …